Wong Lye-Yeng, Kapula Ntemena, He Hao, Guenthart Brandon A, Vitzthum Lucas K, Horst Kathleen, Liou Douglas Z, Backhus Leah M, Lui Natalie S, Berry Mark F, Shrager Joseph B, Elliott Irmina A
Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, Calif.
Department of Radiation Oncology, Stanford University Medical Center, Stanford, Calif.
JTCVS Open. 2023 Oct 31;16:919-928. doi: 10.1016/j.xjon.2023.10.031. eCollection 2023 Dec.
Radiotherapy (RT) is integral to breast cancer treatment, especially in the current era that emphasizes breast conservation. The aim of our study was to determine the incidence of subsequent primary lung cancer after RT exposure for breast cancer over a time span of 3 decades to quantify this risk over time as modern oncologic treatment continues to evolve.
The SEER (Surveillance, Epidemiology, and End Results) database was queried from 1988 to 2014 for patients diagnosed with nonmetastatic breast cancer. Patients who subsequently developed primary lung cancer were identified. Multivariable regression modeling was performed to identify independent factors associated with the development of lung cancer stratified by follow up intervals of 5 to 9 years, 10 to 15 years, and >15 years after breast cancer diagnosis.
Of the 612,746 patients who met our inclusion criteria, 319,014 (52%) were irradiated. primary lung cancer developed in 5556 patients (1.74%) in the RT group versus 4935 patients (1.68%) in the non-RT group. In a multivariable model stratified by follow-up duration, the overall HR of developing subsequent ipsilateral lung cancer in the RT group was 1.14 ( = .036) after 5 to 9 years of follow-up, 1.28 ( = .002) after 10 to 15 years of follow-up, and 1.30 ( = .014) after >15 years of follow-up. The HR of contralateral lung cancer was not increased at any time interval.
The increased risk of developing a primary lung cancer secondary to RT exposure for breast cancer is much lower than previously published. Modern RT techniques may have contributed to the improved risk profile, and this updated study is important for counseling and surveillance of breast cancer patients.
放射治疗(RT)是乳腺癌治疗不可或缺的一部分,尤其是在当前强调保乳的时代。我们研究的目的是确定在30年的时间跨度内,乳腺癌放疗后发生后续原发性肺癌的发生率,以便随着现代肿瘤治疗的不断发展,量化这种风险随时间的变化。
查询1988年至2014年监测、流行病学和最终结果(SEER)数据库中诊断为非转移性乳腺癌的患者。确定随后发生原发性肺癌的患者。进行多变量回归建模,以确定在乳腺癌诊断后5至9年、10至15年和>15年的随访间隔分层中,与肺癌发生相关的独立因素。
在符合我们纳入标准的612746例患者中,319014例(52%)接受了放疗。放疗组有5556例患者(1.74%)发生原发性肺癌,而非放疗组有4935例患者(1.68%)发生原发性肺癌。在按随访持续时间分层的多变量模型中,放疗组在随访5至9年后发生后续同侧肺癌的总体风险比为1.14(P = 0.036),随访10至15年后为1.28(P = 0.002),随访>15年后为1.30(P = 0.014)。对侧肺癌的风险比在任何时间间隔均未增加。
乳腺癌放疗后发生原发性肺癌的风险增加幅度远低于先前发表的结果。现代放疗技术可能有助于改善风险状况,这项更新的研究对于乳腺癌患者的咨询和监测具有重要意义。